Rilastil, in its bid to lead the future of dermatology, has joined forces with FC Barcelona, which is opening up new paths in women's football and basketball.
Rilastil, in keeping with its aim of providing effective dermatological solutions to skin problems and needs in order to improve people's health and quality of life, has joined forces with FC Barcelona women's football team. The values of sport are combined with those of health to spread better habits and, through the players, we celebrate self-improvement, determination, the ability to break down barriers and make dreams come true.
The sponsorship agreement, which will last for three years and will be global in nature, includes the women's football and basketball teams and is mainly focused on promoting skin care, because healthy skin is synonymous with health. In addition to the visibility of Rilastil's corporate image in the context of the two teams it sponsors, the brand will develop actions with the players to help empower people and promote skin care.
"We are delighted to welcome Rilastil to the family of partners supporting the Club's women's sports programme which, for yet another season, continues to break records in terms of revenue generation and public success. Rilastil is a leading brand in the field of dermatology whose values of rigour and innovation fit perfectly with our philosophy. This agreement once again highlights the commercial capacity of FC Barcelona's women's sport, which is in constant evolution and projection and is one of the fundamental pillars for the Club," said Juli Guiu, vice-president of the FC Barcelona Marketing Department.
"We are two partners with the same vision of leadership. FC Barcelona Women is leading the future of football and basketball while Rilastil is leading the future of dermatology. The players are not only the perfect role models of this modernity, they are also examples of the challenges that women in general have had to face and overcome. We are entering a new era, an era of female values and women to whom we have been dedicating our scientific research for over 50 years," said Giuseppe Ganassini, CEO of the ISTITUTO GANASSIN group, to which Rilastil belongs.